Clinical Trial Update: A Study of SHR-1210 in Combination With Carboplatin + Paclitaxel in Subjects With Squamous NSCLC [Phase 3]

View source ↗

Summary

Phase 3 study of SHR-1210 with carboplatin and paclitaxel in squamous non-small cell lung cancer is ongoing, with status not provided.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Cancer
• Non-small Cell Lung Cancer
• Squamous Cell Lung Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• PACLITAXEL (PACLITAXEL)
• SHR-1210 (camrelizumab)

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: Lung Cancer Squamous Cell, Lung Cancer Stage IV | Phase 3 | Status: UNKNOWN